StemCell.Directory
Menu
  • Home
  • Blog
  • Connect
  • FAQ
  • Submit Event
  • Submit Listing
StemCell.Directory
Menu
  • Home
  • Blog
  • Connect
  • FAQ
  • Submit Event
  • Submit Listing

Stem Cells, Cell and Gene Therapy Biotechs to Discuss Capital Formation Strategies and Validation

Published by GP On July 24, 2013

NEW YORK – In a progressive cell therapy environment that has decreasing clinical attrition, next generation and next-to-launch biotechs along with regulators, will be talking about current strategies and approaches to advance the development of stem cells, cell and gene therapies.

Over 250 biotechs, biopharma, research institutions and regulators will gather at the Stem Cells USA & Regenerative Medicine Congress on September 30 – October 1, 2013.

Key speakers include Richard Garr, Neuralstem’s Chief Executive Officer, Paul Laikind, Viacyte’s President, Renier Brentjens, Medical Oncologist at the Memorial Sloan-Kettering Cancer Center, Michael May, CEO of Canada’s Center for the Commercialization of Regenerative Medicine and Mohammad Heidaran from the Office of Cellular, Tissue and Gene Therapies at CBER/FDA.

Leading cell therapy stakeholders will gather this fall to dialogue and brainstorm about effective strategies to continuously move the industry forward and support the boost of new therapies in the space.

Various facets to highlight key needs of the industry are as follows:
• 3 events in 1 – Stem Cells, Cord Blood and Cell Culture parallel programs
• Exhibition showcase floor for technology and solution providers
• Technical on-floor seminars for stem cell, cell and therapy manufacturers and developers looking for better technologies, equipment and processes
• 2-day strategic conference for key decision makers from biotechs, biopharma, regulators and academia

Participants will learn:
• How to implement effective fund-raising strategies
• How to deploy a commercial mindset from the early stages of regenerative medicine development
• How to fast-track regulatory approval
• How new automated and roboticized technologies are resolving scale-up manufacturing challenges
• How to translate academic research into successful therapies

To register or learn more visit www.terrapinn.com/stemcellsusa

About Terrapinn:
Terrapinn is a business media company. Our products are trade exhibitions, conferences, training solutions and electronic and print publications. More information and a schedule of our events can be found at www.terrapinn.com.

  • Share
Categories: News, Stem Cells Tags: biotech, stem cells
← PreviousNext →

Subscribe To Our Newsletter

Subscribe to get latest news from site

Submit Your Listing

Get maximum online exposure for your business by submitting a listing on our directory. Benefit from our audience of visitors who seek the services and products you're promoting. Click here, Submit Listing.

Marketplace

“Adspace

About StemCell.Directory

StemCell.Directory is a Fully Searchable, Human-edited Directory for the entire Stem Cell Industry. We invite all Doctors, Researchers, Corporations, and Associations to join our ever-growing community. Start here

Tags

video UCLA teeth stem cells skin cells reprogramming pluripotent NIH MS mesenchymal liver leukemia ISCO iPSC iPS heart embryonic diabetes cornea cord-blood CIRM cancer bone-marrow ALS

DISCLAIMER

StemCell.Directory disclaims any liability, loss, or risk, directly or indirectly of the application of any of the contents found on this web site. Always consult a medical professional regarding treatment.

© 2023 Stem Cell Directory | Built by Brainguzzle

Sign In

Forgot your password?

Forgot password

Inquiry for
Stem Cells, Cell and Gene Therapy Biotechs to Discuss Capital Formation Strategies and Validation

x